BCC 2023 | Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, discusses areas of unmet need for the use of CDK4/6 inhibitors in patients with HR+/HER2- breast cancer, touching on late-stage relapse, extending adjuvant endocrine treatment and combination approaches. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.